Patents by Inventor Kevin R. Rupprecht

Kevin R. Rupprecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Neutrophil gelatinase-associated lipocalin (NGAL) protein isoforms enriched from urine and recombinant chinese hamster ovary (CHO) cells and related compositions, antibodies, and methods of enrichment, analysis and use
    Patent number: 8394606
    Abstract: A composition comprising neutrophil gelatinase-associated lipocalin (NGAL), which has been enriched from urine, has a molecular weight of about 24.9 kDa to about 25.9 kDa, and comprises a plurality of isoforms having isoelectric points (pIs) ranging from about 5.9 to about 9.1; a composition comprising NGAL, which has been enriched from recombinant Chinese hamster ovary (CHO) cells, has a molecular weight of about 25.9 kDa to about 27.9 kDa, and comprises a plurality of isoforms having pIs ranging from about 5.6 to about 9.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: March 12, 2013
    Assignee: Abbott Laboratories
    Inventors: Salman Ali, Ryan M. Bonn, Frank C. Grenier, Tracey D. Rae, Kevin R. Rupprecht, Hina N. Syed, Bailin Tu, Joan D. Tyner, Ryan F. Workman
  • NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) PROTEIN ISOFORMS ENRICHED FROM URINE AND RECOMBINANT CHINESE HAMSTER OVARY (CHO) CELLS AND RELATED COMPOSITIONS, ANTIBODIES, AND METHODS OF ENRICHMENT, ANALYSIS AND USE
    Publication number: 20100116662
    Abstract: A composition comprising neutrophil gelatinase-associated lipocalin (NGAL), which has been enriched from urine, has a molecular weight of about 24.9 kDa to about 25.9 kDa, and comprises a plurality of isoforms having isoelectric points (pIs) ranging from about 5.9 to about 9.1; a composition comprising NGAL, which has been enriched from recombinant Chinese hamster ovary (CHO) cells, has a molecular weight of about 25.9 kDa to about 27.9 kDa, and comprises a plurality of isoforms having pIs ranging from about 5.6 to about 9.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 13, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Salman Ali, Ryan M. Bonn, Frank C. Grenier, Tracey D. Rae, Kevin R. Rupprecht, Hina N. Syed, Bailin Tu, Joan D. Tyner, Ryan F. Workman
  • Hepatitis C assay utilizing recombinant antigens
    Patent number: 6593083
    Abstract: Unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to HCV. The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.
    Type: Grant
    Filed: October 17, 2000
    Date of Patent: July 15, 2003
    Inventors: Sushil G. Devare, Suresh M. Desai, James M. Casey, Stephen H. Dailey, George J. Dawson, Robin A. Gutierrez, Richard R. Lesniewski, James L. Stewart, Kevin R. Rupprecht
  • Hepatitis C assay utilizing recombinant antigens
    Patent number: 6172189
    Abstract: The present invention provides unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to HCV. The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: January 9, 2001
    Assignee: Abbott Laboratories
    Inventors: Sushil G. Devare, Suresh M. Desai, James M. Casey, Stephen H. Dailey, George J. Dawson, Robin A. Gutierrez, Richard R. Lesniewski, James L. Stewart, Kevin R. Rupprecht